Filing Flows › Arcus Biosciences (RCUS) › Q3 2026 › vs Q3 2025
Arcus Biosciences (RCUS) Q3 2026 vs Q3 2025 (year over year)
Arcus Biosciences's revenue fell $17.0M (-65%) from $26.0M in Q3 2025 to $9.0M in Q3 2026. The biggest changes: License and development services −$12.0M (-60%); Other collaboration −$5.0M (-83%).
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| License and development services | $8.0M | $20.0M | −$12.0M | -60% |
| Other collaboration | $1.0M | $6.0M | −$5.0M | -83% |
| Revenue | $9.0M | $26.0M | −$17.0M | -65% |
| Other income, net | $3.0M | $7.0M | −$4.0M | -57% |
| Net loss | $128M | $135M | −$7.0M | -5% |
| Costs & expenses | $140M | $168M | −$28.0M | -17% |
| Operating costs | $140M | $168M | −$28.0M | -17% |
| Research & development | $117M | $141M | −$24.0M | -17% |
| General & admin | $23.0M | $27.0M | −$4.0M | -15% |
| Operating cash sources | $128M | $135M | −$7.0M | -5% |
| Depreciation & amortization | $2.0M | $2.0M | $0 | 0% |
| Share-based compensation | $16.0M | $14.0M | $2.0M | +14% |
| Working capital & other | $22.0M | $22.0M | $0 | 0% |
| Cash used in operations | $88.0M | $97.0M | −$9.0M | -9% |
| Net loss absorbed | $128M | $135M | −$7.0M | -5% |
Questions
How much did Arcus Biosciences's revenue grow year over year in Q3 2026?
Arcus Biosciences's revenue fell $17.0M (-65%) from $26.0M in Q3 2025 to $9.0M in Q3 2026.
What drove Arcus Biosciences's revenue change in Q3 2026?
License and development services −$12.0M (-60%); Other collaboration −$5.0M (-83%).